Brokerages expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to announce earnings of ($0.02) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Path Holdings’ earnings. Bio-Path Holdings also reported earnings of ($0.02) per share in the same quarter last year. The firm is expected to issue its next earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Bio-Path Holdings will report full year earnings of ($0.08) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.11) per share. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Bio-Path Holdings.

Bio-Path Holdings (NASDAQ:BPTH) last posted its earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by $0.01.

Several equities analysts have weighed in on BPTH shares. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Bio-Path Holdings in a report on Tuesday, July 4th. Zacks Investment Research lowered Bio-Path Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th.

Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC acquired a new position in Bio-Path Holdings during the first quarter worth approximately $105,000. Sabby Management LLC raised its position in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares during the last quarter. Bank of New York Mellon Corp raised its position in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the last quarter. HighTower Advisors LLC raised its position in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after buying an additional 1,741,978 shares during the last quarter. Institutional investors and hedge funds own 21.38% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/16/zacks-analysts-expect-bio-path-holdings-inc-bpth-will-post-earnings-of-0-02-per-share.html.

Shares of Bio-Path Holdings (BPTH) traded down 1.75% on Wednesday, reaching $0.28. The company had a trading volume of 126,649 shares. The company has a 50-day moving average price of $0.37 and a 200-day moving average price of $0.59. Bio-Path Holdings has a 52-week low of $0.26 and a 52-week high of $1.71. The firm’s market capitalization is $28.02 million.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Get a free copy of the Zacks research report on Bio-Path Holdings (BPTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.